Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
Phase 2
Recruiting
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05599295
- Locations
- ๐ต๐น
Hospital de Braga, Braga, Portugal
๐บ๐ธTampa General Hospital, Tampa, Florida, United States
๐บ๐ธMount Sinai Beth Israel, New York, New York, United States
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT02134301
- Locations
- ๐บ๐ธ
Arkansas Children's Hospital, Little Rock, Arkansas, United States
๐บ๐ธChildrens Hospital of Orange County, Orange, California, United States
๐บ๐ธRady Children's Hospital, San Diego, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath